Stock Monitor: Peregrine Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Mesoblast Ltd (NASDAQ: MESO), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=MESO as the Company's latest news hit the wire. On December 15, 2017, the Company declared that it has granted TiGenix N.V. exclusive access to certain of its patents to support global commercialization of the adipose-derived mesenchymal stem cell product Cx601 for the local treatment of fistulae. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

is currently working on the research report for Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), which also belongs to the Healthcare sector as the Company Mesoblast. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=PPHM

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Mesoblast most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=MESO

Agreement Details

The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix's current development and commercialization partner ex-United States. TiGenix will pay Mesoblast up to ?20 million (approximately USD$24 million) in payments, with ?5 million upfront, ?5 million within 12 months, and up to ?10 million in product regulatory milestones. In addition, the latter will receive single digit royalties on net sales of Cx601.

TiGenix to Have a Stronger Intellectual Property Position with Newly-Added IP Protection

Eduardo Bravo, Chief Executive Officer of TiGenix, stated that this exclusive license agreement with Mesoblast will broaden TiGenix's IP protection for Cx601 as the Company moves closer to commercialization in Europe. Eduardo added that TiGenix continues advancing its global pivotal Phase-3 clinical trial to support a future Biologics License Application (BLA) to the US FDA and are also pursuing the development of new indications for Cx601 to expand its potential market. With this newly-added IP protection, TiGenix now has a stronger intellectual property position that supports the use of Cx601 for treatment of all fistulae.

Cx601 Received Positive CHMP's Opinion to Treat Complex Perianal Fistulas in Crohn's Disease

On December 15, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), in conjunction with the Committee for Advanced Therapies (CAT) has adopted a positive opinion recommending a marketing authorization for investigational compound Cx601 (darvadstrocel). This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP's opinion in Europe.

What is Fistula?

A fistula is an abnormal connection between two hollow spaces such as blood vessels, intestines, or other hollow organs. Fistulas are usually caused by injury or surgery, but they can also result from an infection or inflammation. Fistulas are generally a disease condition, but they may be surgically created for therapeutic reasons.

About Cx601

Cx601, TiGenix's lead product candidate is a local administration of expanded adipose-derived stem cells (eASCs) for the treatment of complex perianal fistulas in Crohn's disease patients. The treatment is administered as a single dose and has been proven to have long-term efficacy in the healing of complex perianal fistulas in Crohn's disease patients. It has been designated as an orphan drug by the EMA and SwissMedic, in Switzerland. TiGenix retains full rights to the product in the US as well as to the development of Cx601 in other indications. In July 2016, Takeda Pharmaceuticals acquired an exclusive right to develop and commercialize Cx601 for complex perianal fistulas in Crohn's disease patients outside of the US.

About Mesoblast Limited

Founded in 2004 and based in Melbourne, Australia, Mesoblast is a world leader in innovative cell-based medicines. The Company has established the industry's most clinically advanced and diverse portfolio of cell-based products, and has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

About TiGenix N.V.

Established in 2000, TiGenix is a biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need. The Company is headquartered in Leuven, Belgium and has operations in Madrid, Spain.

Stock Performance Snapshot

December 15, 2017 - At Friday's closing bell, Mesoblast's stock climbed 1.67%, ending the trading session at $5.48.

Volume traded for the day: 50.60 thousand shares, which was above the 3-month average volume of 36.41 thousand shares.

Stock performance in the last month ? up 9.60%; previous three-month period ? up 1.48%; and year-to-date - up 2.43%

After last Friday's close, Mesoblast's market cap was at $500.54 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.0% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors